


Supplementary Figure S3



Supplementary Figure S3. Tumor growth kinetics of individual *de novo* MPNSTs during therapy. Wild-type mice bearing *de novo* MPNSTs were initiated by CRISPR editing of *Nf1/Ink4a/Arf* in the sciatic nerve. Once tumors reached ~250 mm³, mice were treated daily with vehicle (V), 100 mg/kg palbociclib (P), 1 mg/kg mirdametinib (M), or the combination of palbociclib plus mirdametinib (Combo). Daily tumor volumes (mm³) were recorded during therapy with the indicated treatments for each mouse examined in Figure 3. The total number of mice per group is denoted (n).